Most commentary on Brexit and cannabis treats the UK and the EU as two separate markets. In practice they are one system that has been pulled apart, and the friction between the two sides is now the single largest commercial variable for anyone trying to build a cannabinoid business across the Channel.
The science is shared. The clinicians are in regular contact. The brands often want to sell into both jurisdictions. What has changed is the paperwork, the product classifications, the VAT treatment, the clinical framework, and the pharmacy channel structure, all of which now diverge. The result is that a product approved on one side of the bridge can be stranded on the other, and a distributor with strong German pharmacy relationships can be entirely absent from Boots.
This is not a gap that closes by itself. It closes when people with working knowledge of both systems take the time to move between them.
Where the UK and the EU have actually diverged
The headline divergences are by now familiar to anyone in the industry, but worth stating plainly because they drive nearly every commercial decision.
- Novel foods. The UK's Food Standards Agency runs its own novel food authorisation regime for ingestible CBD, with a validated public list, provisional authorisations, and an ongoing backlog. The EU's European Food Safety Authority paused most cannabinoid novel food assessments in 2022 pending toxicology clarification and has only recently begun moving again. The two lists do not match. A product legal in one jurisdiction may be unsellable, or only provisionally sellable, in the other.
- Medical cannabis framework. The UK operates a specials pathway, with private prescriptions through specialist clinics the dominant route. Germany reclassified cannabis in April 2024 and has since seen pharmacy sales surpass one billion euros, moving the German market firmly into pharmacy-first medical-grade territory. Access, reimbursement, and prescriber training look different on each side.
- Labelling and health claims. The UK inherited EU nutrition and health claims regulation at Brexit and has retained most of it, but UK-specific amendments and enforcement discretion have begun to accumulate. What a label can say about a cannabinoid product in Dusseldorf is not identical to what it can say in Dundee.
- Logistics and customs. Border procedures, VAT at import, product-of-origin declarations, and certificate-of-analysis acceptance have all become more involved since 2021. These are solvable problems, but they are solvable by people who have actually done them.
None of this is catastrophic for a well-organised brand. All of it is expensive for a brand trying to manage it at arm's length.
The commercial consequence
The practical result is that brands increasingly need a dual-track strategy rather than a single European approach. A good UK launch and a good EU launch are often two different products, two different channel structures, and two different regulatory dossiers, even when the active ingredients are identical.
Most brands discover this the hard way. They build for one side of the bridge first, then look up eighteen months later and realise the other side was supposed to be half of the addressable market. The cost of that delay in a market growing at north of twenty percent compound is material.
The friction between the two sides is now the single largest commercial variable for anyone trying to build a cannabinoid business across the Channel.
Who can actually operate on both sides
There are three kinds of people in this industry right now who can move between the UK and the EU with any fluency.
- Large legal and regulatory firms with dedicated cannabis practices, typically billing at city rates and structured to advise rather than execute.
- In-house regulatory affairs teams at the few cannabinoid majors that have been building for long enough to justify them. Competent, but narrowly scoped to the products they own.
- A small number of independent operators who have actually sold product into both jurisdictions, negotiated both sets of distribution contracts, and spent time at both sets of trade shows.
The third group is the smallest and the most useful to emerging brands. The work is unglamorous: it involves translating between regulatory vocabularies, making introductions between clinicians on both sides, understanding which pharmacy groups actually carry the product versus listing it, and knowing which trade shows are worth attending and which are social theatre.
What this looks like in practice
The concrete pieces of bridge work I am most often asked about are these:
- Channel mapping. Which UK health food, pharmacy, and clinic channels map onto which German, Dutch, French, and Nordic counterparts. The answer is rarely symmetric, and almost never the one brands expect.
- Clinician networks. Specialist clinicians on both sides are already in contact, but the introductions that matter for a brand are usually the ones that are not public. These take time to earn.
- Distribution economics. Margins, payment terms, minimum orders, and listing fees look different in each market. So does the willingness of distributors to carry a new brand on consignment.
- Formulation portability. Whether a product formulated for the UK novel foods list can be reformulated for a specific EU member state without losing its clinical rationale. Sometimes yes, sometimes no, almost always worth asking before the first batch is produced.
None of this is exotic. It is the ordinary work of operating in two adjacent regulated markets that used to be one. The reason it creates commercial advantage is that most of the industry is still working on one side or the other, not across.
A practical note
My own position in this, London-born, Netherlands-based, a British citizen with an EU residency, is not unusual in demographic terms. It is unusual in professional terms, because very few operators in the cannabinoid industry have happened to end up with a working tax base, language, and clinical network on both sides of the Channel at the same time. For brands trying to launch across the bridge, that turns out to matter more than one would expect.
The 2026 Icelandic Elements whitepaper sets out the clinical framework for cannabinoid therapeutics in women's hormonal health across both jurisdictions. The commercial implication is that the bridge is open for work, and the operators who build for both sides first are the ones who will still be standing when the market consolidates.
If you are a UK brand looking at Europe, or a European brand looking at the UK, I would be glad to talk.